25-hydroxyvitamin D levels, race, and the progression of kidney disease.
暂无分享,去创建一个
N. Powe | T. Hostetter | B. Astor | P. Muntner | E. Michos | M. Melamed
[1] C. Zoccali,et al. Vitamin D levels and patient outcome in chronic kidney disease. , 2009, Kidney international.
[2] B. Astor,et al. 25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population , 2008 .
[3] D. V. von Mühlen,et al. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. , 2008, The American journal of clinical nutrition.
[4] D. Reich,et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.
[5] E. Rimm,et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. , 2008, Archives of internal medicine.
[6] P. Raggi,et al. Serum 25-Hydroxyvitamin D Levels and the Prevalence of Peripheral Arterial Disease: Results from NHANES 2001 to 2004 , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[7] Michael J. Pencina,et al. Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.
[8] B. Kestenbaum,et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] A. Mitrakou,et al. The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults , 2007, Diabetes Care.
[10] Keith C. Norris,et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. , 2007, Archives of internal medicine.
[11] Edward Giovannucci,et al. Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension , 2007, Hypertension.
[12] J. Allison,et al. Survival advantage of black patients with kidney disease after acute myocardial infarction. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[13] J. Alexander,et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. , 2006, Kidney international.
[14] S. Harris,et al. Vitamin D and African Americans. , 2006, The Journal of nutrition.
[15] G. Camussi,et al. Treatment with 1, 25-Dihydroxyvitamin D3 Preserves Glomerular Slit Diaphragm-Associated Protein Expression in Experimental Glomerulonephritis , 2005, International journal of immunopathology and pharmacology.
[16] N. Powe,et al. Racial disparities in the optimal delivery of chronic kidney disease care. , 2005, The Medical clinics of North America.
[17] H. Krumholz,et al. Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites , 2005, Circulation.
[18] Keith C. Norris,et al. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. , 2005, Ethnicity & disease.
[19] B. Dawson-Hughes. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. , 2004, The American journal of clinical nutrition.
[20] M. Sowers,et al. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. , 2004, Diabetes care.
[21] S. Heymsfield,et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. , 2004, Metabolism: clinical and experimental.
[22] Guilin Qiao,et al. Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[23] E. Vittinghoff,et al. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. , 2003, Journal of the American Society of Nephrology : JASN.
[24] H. Trivedi,et al. Discrepancy in the Epidemiology of Nondiabetic Chronic Renal Insufficiency and End-Stage Renal Disease in Black and White Americans: The Third National Health and Nutrition Examination Survey and United States Renal Data System , 2003, American Journal of Nephrology.
[25] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[26] T. Doi,et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] N. Powe,et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. , 2002, Journal of the American Society of Nephrology : JASN.
[28] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .
[29] Tom Greene,et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] B. Dawson-Hughes,et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. , 2002, Bone.
[31] 槙林 弘之郎. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis , 2002 .
[32] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.
[33] H. Sollinger,et al. 1,25-(OH2)D3 Alters the Transforming Growth Factor β Signaling Pathway in Renal Tissue , 2001 .
[34] G. Camussi,et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. , 2001, Kidney international.
[35] H. Minne,et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.
[36] H. Sollinger,et al. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. , 2001, The Journal of surgical research.
[37] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[38] J. Mathews,et al. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. , 1999, Kidney international.
[39] L. Chambless,et al. A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. , 1999, Archives of internal medicine.
[40] Arya M. Sharma,et al. Ultraviolet B and blood pressure , 1998, The Lancet.
[41] E. Ritz,et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. , 1998, Kidney international.
[42] R. Lindsay,et al. Resistance to Bone Resorbing Effects of PTH in Black Women , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] G. Beck,et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.
[44] H. Rasmussen,et al. Calcium absorption responses to calcitriol in black and white premenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.
[45] J. Kanis,et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure , 1995, BMJ.
[46] B. Brenner,et al. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[47] M. Pasquali,et al. No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.
[49] R. Bouillon,et al. Partial prevention of active Heymann nephritis by lα, 25 dihydroxyvitamin D3 , 1993, Clinical and experimental immunology.
[50] P. Whelton,et al. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. , 1992, JAMA.
[51] K. Maurer,et al. Sample design: Third National Health and Nutrition Examination Survey. , 1992, Vital and health statistics. Series 2, Data evaluation and methods research.
[52] S. Lillevang,et al. Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric‐chloride‐induced autoimmune disease in the BN rat , 1992, Clinical and experimental immunology.
[53] J. Lemire,et al. 1,25-Dihydroxyvitamin D3 Attenuates of Expression of Experimental Murine Lupus of MRL/1 Mice , 1992 .
[54] J. Lemire,et al. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. , 1992, Autoimmunity.
[55] R. Neuwirth,et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. , 1992, JAMA.
[56] J. Adams,et al. INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.
[57] M. Kodroff,et al. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure. , 1981, Pediatrics.
[58] W. Loomis. Skin-Pigment Regulation of Vitamin-D Biosynthesis in Man , 1967, Science.